Trial Profile

CONSORTIUM - A Double-Blind Placebo-Controlled Phase 2 Study of VE303 for Prevention of Recurrent Clostridium (Clostridioides) Difficile Infection

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 28 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs VE 303 (Primary)
Indications Clostridium difficile infections
Focus Adverse reactions; Therapeutic Use
Acronyms CONSORTIUM
Sponsors Vedanta Biosciences

Most Recent Events

23 Jan 2025 According to a Vedanta Biosciences media release, Results from this study informed the design and dose selection for the global, pivotal Phase 3 study, RESTORATiVE303.
23 Jan 2025 According to a Vedanta Biosciences media release, the additional results from this study were published in Nature Medicine.
23 Jan 2025 Results presented in the Vedanta Biosciences Media Release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com